Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells

Journal of Experimental Medicine

Volumn 195, Issue 10, 2002, Pages 1279-1288

  Schuler Thurner, Beatrice ^a   Schultz, Erwin S ^a   Berger, Thomas G ^a   Weinlich, Georg ^b   Ebner, Susanne ^b   Woerl, Petra ^a   Bender, Armin ^a   Feuerstein, Bernadette ^a   Fritsch, Peter O ^b   Romani, Nikolaus ^b   Schuler, Gerold ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

CD4+ T cells; Dendritic cells; T helper cells; Tumor immunity; Vaccination

Indexed keywords

ANTIGEN KLH; CANCER VACCINE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA ANTIGEN; MELANOMA ANTIGEN 3.DP4; MELANOMA ANTIGEN 3.DR13; PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL MATURATION; CLINICAL ARTICLE; CLINICAL TRIAL; CRYOPRESERVATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; MELANOMA; MOLECULAR INTERACTION; MONOCYTE; MULTICENTER STUDY; PRIORITY JOURNAL; SIDE EFFECT; SKIN METASTASIS; TH1 CELL; TUMOR IMMUNITY; VACCINATION;

ADULT; AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON TYPE II; INTERLEUKIN-2; INTERLEUKIN-4; KINETICS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; TH1 CELLS; VACCINATION;

EID: 0037141023     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20012100     Document Type: Article

References (34)

1. Tumor antigens recognized by T cells
2. A new era for cancer immunotherapy based on the genes that encode cancer antigens
3. + T cell responses in antitumor immunity
4. + T cells in antitumor immunity
5. Vaccines and vaccination
6. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN-γ receptor expression by nonhematopoietic cells
7. Active immunization against cancer with dendritic cells: The near future
8. Dendritic cells as vectors for therapy
9. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
10. + melanoma patients by mature monocyte-derived dendritic cells
11. A comparison of two types of dendritic cell as adjuvants for the induction of melanomaspecific T-cell responses in humans following intranodal injection
12. A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use
13. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application
14. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
15. + T lymphocytes
16. + cytolytic T lymphocytes
17. + T cells recognize nonmutated HLADR-restricted tyrosinase epitopes
18. Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells
19. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
20. + progenitor-derived dendritic cell vaccine
21. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
22. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients
23. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses
24. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma
25. Vaccination of patients with B-cell lymphoma using autologous antigenpulsed dendritic cells
26. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients
27. Production of IL-12 by human monocyte-derived dendritic cells is optimal when the stimulus is given at the onset of maturation, and is further enhanced by IL-4
28. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells
29. Kinetics of dendritic cell activation: Impact on priming of TH1, TH2 and nonpolarized T cells
30. Several common HLA-DR types share largely overlapping peptide binding repertoires
31. DRB1*15-DR15(2)
32. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens
33. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo
34. Future directions for allergen immunotherapy